EUVIMEDEUVIMED entdecken
Crossref

Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer

Rika Nakahashi-Ouchida iD, Hiromi Mori, Yoshikazu Yuki, Tomonori Machita, Yuko Katakai, Shingo Umemoto iD, Yohei Uchida iD, Tomoyuki Yamanoue, Shin-Ichi Sawada iD, Kazuya Ishige, Takashi Miyazaki, Kohtaro Fujihashi iD und 4 weitere

Science Translational Medicine · 12.11.2025 · 17 (824)

DOI: 10.1126/scitranslmed.ado8840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 12.11.2025. Verfasst von Rika Nakahashi-Ouchida und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Mucosal Vaccinology, Chiba University Hospital, Chuo-ku, Chiba, 260-8670, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Polyethyleneimine, Polyethylene Glycols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: NIDDK NIH HHS, Japan Agency for Medical Research and Development, the Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic vaccines against cervical cancer caused by human papillomavirus (HPV) are still an unmet medical need, despite a prophylactic HPV vaccine being available, and the now-licensed systemic vaccines may have a limited effect on the reproductive tract. To specifically inhibit cervical cancer development, the concept of mucosal immunity based on the reproductive-respiratory axis was adopted to develop a nasal HPV therapeutic vaccine. We used a cationic nanogel for the nasal vaccine delivery system and targeted HPV16 E7, an oncoprotein in HPV-driven cervical cancer to demonstrate the feasibility of a nasal therapeutic vaccine. The vaccine was combined with cyclic di–adenosine monophosphate as a cell-mediated immunity-inducing adjuvant. Intranasal immunization with the nanogel vaccine induced E7-specific CD4 + and CD8 + T cells in mouse cervicovaginal tissue. An antitumor effect due to the infiltration of vaccine-induced E7-specific T cells was also observed in an orthotopic tumor model in mice. Furthermore, intranasal immunization of nonhuman primates with the nanogel vaccine using a spray device that is also applicable to humans induced E7-specific T cells in the reproductive tissues. Our findings demonstrated that this nasal therapeutic vaccine effectively controlled cervical cancer and will contribute to preclinical evidence for clinical testing in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesPolyethyleneiminePolyethylene GlycolsFemaleAnimalsAdministration, IntranasalHumansNanogelsMicePapillomavirus E7 ProteinsCationsCD8-Positive T-LymphocytesMice, Inbred C57BLPapillomavirus Infections

Substanzen

Papillomavirus VaccinesNanogelsPolyethyleneiminePolyethylene GlycolsPapillomavirus E7 ProteinsCationspolyethylene glycol polyethyleneimine nanogel

Autor:innen und Institutionen

  • Department of Human Mucosal Vaccinology, Chiba University Hospital, Chuo-ku, Chiba, 260-8670, Japan.
  • Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, Chuo-ku, Chiba, 260-8670, Japan.
  • Research Institute of Disaster Medicine, Chiba University, Chuo-ku, Chiba, 260-8670, Japan.
  • Division of Mucosal Vaccines, International Research and Development Center for Mucosal Vaccines, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.
  • Division of Mucosal Immunology, IMSUT Distinguished Professor Unit, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.
  • HanaVax Inc., Toyonaka, Osaka, 561-0825, Japan.

ORCID-Profile: Rika Nakahashi-Ouchida, Shingo Umemoto, Yohei Uchida, Shin-Ichi Sawada, Kohtaro Fujihashi, Yasuhiro Yasutomi, Kei Kawana, Hiroshi Kiyono

Förderung

  • NIDDK NIH HHS
  • Japan Agency for Medical Research and Development
  • the Japan Agency for Medical Research and Development
  • University of Tokyo
  • HanaVax
  • Japan Society for the Promotion of Science
  • Chiba University-UC San Diego Center for Mucosal Immunology, Allergy and Vaccines (cMAV) Program
  • Chiba University and Shionogi Human Mucosal Vaccinology Program

Zitieren

APA

Nakahashi-Ouchida, R., Mori, H., Yuki, Y., Machita, T., Katakai, Y., Umemoto, S., Uchida, Y., Yamanoue, T., Sawada, S. I., Ishige, K., Miyazaki, T., Fujihashi, K., Akiyoshi, K., Yasutomi, Y., Kawana, K., & Kiyono, H. (2025). Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer. Science Translational Medicine, 17(824). https://doi.org/10.1126/scitranslmed.ado8840

Vancouver

Nakahashi-Ouchida R, Mori H, Yuki Y, Machita T, Katakai Y, Umemoto S, et al. Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer. Science Translational Medicine. 2025;17(824). doi:10.1126/scitranslmed.ado8840

BibTeX
@article{NakahashiOuchida2025,
  author = {Nakahashi-Ouchida, Rika and Mori, Hiromi and Yuki, Yoshikazu and Machita, Tomonori and Katakai, Yuko and Umemoto, Shingo and Uchida, Yohei and Yamanoue, Tomoyuki and Sawada, Shin-Ichi and Ishige, Kazuya and Miyazaki, Takashi and Fujihashi, Kohtaro and Akiyoshi, Kazunari and Yasutomi, Yasuhiro and Kawana, Kei and Kiyono, Hiroshi},
  title = {Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {824},
  doi = {10.1126/scitranslmed.ado8840}
}
Kostenlos starten →